Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance

被引：0
作者：
C Palmieri
O Gojis
B Rudraraju
C Stamp-Vincent
D Wilson
S Langdon
C Gourley
D Faratian
机构：
[1] Institute of translational Medicine,Department of Molecular and Clinical Cancer Medicine
[2] University of Liverpool,Division of Cancer
[3] Cancer Research UK Laboratories,Edinburgh Breakthrough Research Unit and Division of Pathology
[4] Imperial College London,undefined
[5] Du Cane Road,undefined
[6] London,undefined
[7] UK,undefined
[8] University of Edinburgh,undefined
[9] University of Edinburgh Cancer Research UK Centre,undefined
[10] Institute of Genetics and Molecular Medicine,undefined
[11] University of Edinburgh,undefined
来源：
British Journal of Cancer | 2013年 / 108卷
关键词：
ovarian cancer; SRC3; platinum; resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2039 / 2044
页数：5
相关论文
共 50 条
  • [31] COPS5 Conferred the Platinum Resistance in Epithelial Ovarian Cancer
    Zhang, Hongqin
    Yan, Tianqing
    Zhong, Ailing
    Guo, Lin
    Lu, Renquan
    CURRENT ISSUES IN MOLECULAR BIOLOGY, 2022, 44 (09) : 3948 - 3958
  • [32] Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients
    Felisiak-Golabek, Anna
    Rembiszewska, Alina
    Rzepecka, Iwona K.
    Szafron, Lukasz
    Madry, Radoslaw
    Murawska, Magdalena
    Napiorkowski, Tomasz
    Sobiczewski, Piotr
    Osuch, Beata
    Kupryjanczyk, Jolanta
    JOURNAL OF OVARIAN RESEARCH, 2011, 4
  • [33] TCF12 overexpression as a poor prognostic factor in ovarian cancer
    Gao, Sainan
    Bian, Tingting
    Zhang, Yuquan
    Su, Min
    Liu, Yifei
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (09)
  • [34] Survivin Expression as a Prognostic Factor in Patients With Epithelial Ovarian Cancer or Primary Peritoneal Cancer Treated With Neoadjuvant Chemotherapy
    Gasowska-Bodnar, Agnieszka
    Bodnar, Lubomir
    Dabek, Andrzej
    Cichowicz, Marzena
    Jerzak, Malgorzata
    Cierniak, Szczepan
    Kozlowski, Wojciech
    Baranowski, Wlodzimierz
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (04) : 687 - 696
  • [35] Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer
    Marx, D
    Meden, H
    Ziemek, T
    Lenthe, T
    Kuhn, W
    Schauer, A
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (06) : 845 - 850
  • [36] EPIDERMAL GROWTH-FACTOR RECEPTOR EXPRESSION IN NORMAL OVARIAN EPITHELIUM AND OVARIAN-CANCER .1. CORRELATION OF RECEPTOR EXPRESSION WITH PROGNOSTIC FACTORS IN PATIENTS WITH OVARIAN-CANCER
    BERCHUCK, A
    RODRIGUEZ, GC
    KAMEL, A
    DODGE, RK
    SOPER, JT
    CLARKEPEARSON, DL
    BAST, RC
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1991, 164 (02) : 669 - 674
  • [37] High co-expression of SLC7A11 and GPX4 as a predictor of platinum resistance and poor prognosis in patients with epithelial ovarian cancer
    Wu, Xiaodong
    Shen, Shizhen
    Qin, Jiale
    Fei, Weidong
    Fan, Fengyun
    Gu, Jiaxin
    Shen, Tao
    Zhang, Tao
    Cheng, Xiaodong
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2022, 129 : 40 - 49
  • [38] Reverting doxorubicin resistance in colon cancer by targeting a key signaling protein, steroid receptor coactivator
    Xiong, Sang
    Xiao, Gong-Wei
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 15 (04) : 3751 - 3758
  • [39] Distinct expression and prognostic value of members of the epidermal growth factor receptor family in ovarian cancer
    Zhou, Quan
    Hou, Chao-Nan
    Yang, Huai-Jie
    He, Ze
    Zuo, Man-Zhen
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 6937 - 6948
  • [40] Human epidermal growth factor receptor 3 expression in patients with epithelial ovarian cancer: a potential target for ovarian mucinous and clear cell carcinoma
    Sato, Sho
    Shintani, Daisuke
    Kaneda, Yuki
    Nakamura, Ryuichi
    Katoh, Tomomi
    Yano, Mitsutake
    Hanaoka, Mieko
    Yagishita, Shigehiro
    Yasuda, Masanori
    Nagata, Motoko
    Hasegawa, Kosei
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, : 805 - 813
12345